Are you Dr. Lohr?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 36 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
Medical Oncology, Dfci, Smith 353
Boston, MA 02115Phone+1 617-632-3485
Summary
- Dr. Jens Lohr, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts, Utah, and California. He is affiliated with Dana-Farber Cancer Institute and Brigham and Women's Hospital.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2012
University of California (San Francisco)Residency, Internal Medicine, 2006 - 2008
Ruprecht Karl University Faculty of MedicineClass of 1997
Certifications & Licensure
CA State Medical License 2009 - 2026
UT State Medical License 2024 - 2026
MA State Medical License 2010 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.Andrew J Yee, Jacob P Laubach, Erica L Campagnaro, Brea C Lipe, Omar Nadeem
Blood Advances. 2024-12-03 - 1 citationsDual role of signaling pathways in myeloma requires cell type-specific targeting of ligand-receptor interactions.Pablo Hernandez-Lopez, Tushara Vijaykumar, Praveen Anand, Daniel Auclair, Julia Frede
Blood Advances. 2024-06-25 - 32 citationsLoss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering.Li Li, Vakul Mohanty, Jinzhuang Dou, Yuefan Huang, Pinaki P Banerjee
Science Advances. 2023-07-28
Press Mentions
American Thyroid Association Awards ThyCa Research Grant to Jens Lohr, MD, PhD, Dana Farber Cancer InstituteAugust 9th, 2017
